NCT07306663 2025-12-29
ESO-Nanjing7
Jiangsu Cancer Institute & Hospital
Phase 3 Active not recruiting
Clinical Trials
11 trialsNCT05383482 2025-11-17
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
Laekna Limited
Phase 1/2 Completed
NCT05357846 2025-06-12
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
Sun Yat-sen University
Phase 3 Recruiting
NCT06718205 2024-12-05
Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University
Phase 2 Recruiting
NCT06413342 2024-07-16
Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
Zhejiang Cancer Hospital
Phase 2 Recruiting
NCT06403878 2024-05-08
Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer
Sichuan University
Phase 2 Recruiting
NCT06161909 2023-12-08
Postoperative Immune Maintenance Therapy for Esophageal Squamous Cell Carcinoma After Radical Resection
Fujian Medical University Union Hospital
Phase 3 Unknown
NCT06152978 2023-12-01
A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma
Fudan University
Phase 2 Not yet recruiting
NCT03748134 2023-10-24
Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT06015035 2023-08-29
Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer
Tang-Du Hospital
Phase 2 Completed
NCT03946969 2022-07-19
Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown